Top

European Archives of Psychiatry and Clinical Neuroscience

Published in:

01-03-2012 | Letter to the Editor

Is symptomatic treatment an option for a boy with clinically significant psychotic-like experiences and depressed mood? Comment on Ruhrmann et al., “intervention in at-risk states for developing psychosis.” (Eur Arch Psychiatry Clin Neurosci 260 Suppl 2:S90–94)

Authors: Hsiang-Yuan Lin, Yen-Nan Chiu, Chen-Chung Liu

Published in: European Archives of Psychiatry and Clinical Neuroscience | Issue 2/2012

Excerpt

Dear Sirs, …

Findling RL, Robb A, Nyilas M, Forbes RA, Jin N, Ivanova S, Marcus R, McQuade RD, Iwamoto T, Carson WH (2008) A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry 165:1432–1441PubMedCrossRef

Fusar-Poli P, Valmaggia L, McGuire P (2007) Can antidepressants prevent psychosis? Lancet 370:1746–1748PubMedCrossRef

Kobayashi H, Morita K, Takeshi K, Koshikawa H, Yamazawa R, Kashima H, Mizuno M (2009) Effects of aripiprazole on insight and subjective experience in individuals with an at-risk mental state. J Clin Psychopharmacol 29:421–425PubMedCrossRef

McGorry PD, Yung A, Phillips L (2001) Ethics and early intervention in psychosis: keeping up the pace and staying in step. Schizophr Res 51:17–29PubMedCrossRef

Meyer SE, Bearden CE, Lux SR, Gordon JL, Johnson JK, O’Brien MP, Niendam TA, Loewy RL, Ventura J, Cannon TD (2005) The psychosis prodrome in adolescent patients viewed through the lens of DSM-IV. J Child Adolesc Psychopharmacol 15:434–451PubMedCrossRef

Moreno C, Arango C, Parellada M, Shaffer D, Bird H (2007) Antidepressants in child and adolescent depression: where are the bugs? Acta Psychiatr Scand 115:184–195PubMedCrossRef

Ruhrmann S, Schultze-Lutter F, Bechdolf A, Klosterkotter J (2010) Intervention in at-risk states for developing psychosis. Eur Arch Psychiatry Clin Neurosci 260(Suppl 2):S90–94PubMedCrossRef

Ruhrmann S, Schultze-Lutter F, Klosterkotter J (2010) Probably at-risk, but certainly ill–advocating the introduction of a psychosis spectrum disorder in DSM-V. Schizophr Res 120:23–37PubMedCrossRef

Woods SW, Tully EM, Walsh BC, Hawkins KA, Callahan JL, Cohen SJ, Mathalon DH, Miller TJ, McGlashan TH (2007) Aripiprazole in the treatment of the psychosis prodrome: an open-label pilot study. Br J Psychiatry Suppl 51:s96–s101CrossRef

10.

Yung AR, McGorry PD (1996) The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophr Bull 22:353–370PubMed

Title: Is symptomatic treatment an option for a boy with clinically significant psychotic-like experiences and depressed mood? Comment on Ruhrmann et al., “intervention in at-risk states for developing psychosis.” (Eur Arch Psychiatry Clin Neurosci 260 Suppl 2:S90–94)
Authors: Hsiang-Yuan Lin
Yen-Nan Chiu
Chen-Chung Liu
Publication date: 01-03-2012
Publisher: Springer-Verlag
Published in: European Archives of Psychiatry and Clinical Neuroscience / Issue 2/2012
Print ISSN: 0940-1334
Electronic ISSN: 1433-8491
DOI: https://doi.org/10.1007/s00406-011-0210-x

At a glance: The STEP trials

Springer Medicine

Is symptomatic treatment an option for a boy with clinically significant psychotic-like experiences and depressed mood? Comment on Ruhrmann et al., “intervention in at-risk states for developing psychosis.” (Eur Arch Psychiatry Clin Neurosci 260 Suppl 2:S90–94)

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2012

General and domain-specific neurocognitive impairments in deficit and non-deficit schizophrenia

Dissociable and common deficits in inhibitory control in schizophrenia and bipolar disorder

A promoter variant of SHANK1 affects auditory working memory in schizophrenia patients and in subjects clinically at risk for psychosis

Differential expression of HINT1 in schizophrenia brain tissue

Investigation of schizophrenic patients from Istanbul, Turkey for the presence of West Nile virus

Descriptive analyses of the aripiprazole arm in the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE)